Do you have multiple myeloma (MM)? Has your MM returned after responding to initial treatment (relapsed) or is not responding to treatment (refractory)? If so, you may be able to participate in this cell therapy research study to learn more about using modified immune cells as possible treatment.

The purpose of this study is to determine the recommended ABBV-400 dose when ABBV-400 is given alone (monotherapy) in Stage 1, and to assess if ABBV-400 monotherapy is a safe and effective treatment compared to the standard of care (SOC) LONSURF [Trifluridine and Tipiracil] plus Bevacizumab in subjects with c-Met overexpressed (level of c-Met protein in your tumor cells is increased) uncontrolled metastatic colorectal cancer in Stage 2 of the study plan.

Do you have metastatic colorectal cancer? Does your cancer lack certain mutations? If so, you might be eligible to take part in a trial to look at the effects of an investigational anticancer drug given with normal therapy.

Do you have recurring Chronic Lymphocytic Leukemia? If so, you may be able to take part in a study on two medicines to treat patients whose chronic lymphocytic leukemia has come back. We will also check if this treatment is safe for treatment.

Do you have thyroid cancer? If so, you may be eligible to participate in a research study to see which targeted therapy will work better to prolong the time until your tumor grows or spreads, after initial treatment.

Have you been diagnosed with early-stage breast cancer or ductal carcinoma in situ (DCIS) and have undergone breast conserving surgery (lumpectomy). If so this may be the research for you!! You may be able to take part in a research study to evaluate the effects of the tumor bed boost when given at the same time (called a simultaneous integrated boost, SIB) with the WBI, as opposed to after the WBI.

Do you have incurable, metastatic, or recurrent head and neck squamous cell carcinoma? If so, you may be able to participate in a study to evaluate the addition of the anti-cancer drug, Cetuximab, to standard of care treatment.

The purpose of this study to see if the drug ruxolitinib with the drugs tacrolimus and methotrexate given before and following a peripheral blood stem cell transplant will prevent graft-versus-host disease (GVHD), a serious complication of a stem cell transplant, better than the drugs post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil.

If you have a solid tumor that has not responded to other treatments and have no remaining therapy options, you may be eligible for the trial. Participants will receive the study drug at no cost.

The purpose of this study is to see if adding LY3537982 to standard cancer treatments works better than just using the standard treatments alone for people with advanced non-small cell lung cancer (NSCLC) who have not yet been treated.